Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review

Crit Rev Food Sci Nutr. 2023;63(7):862-872. doi: 10.1080/10408398.2021.1955654. Epub 2021 Jul 22.

Abstract

The microbial-derived products, including short chain fatty acids, lipopolysaccharide and secondary bile acids, have been shown to participate in the regulation of hepatic lipid metabolism. Previous studies have demonstrated that prebiotics, such as oligosaccharide and inulin, have abilities to change the concentration of microbial-derived products through modulating the microbial community structure, thus controlling body weight and alleviating hepatic fat accumulation. However, recent evidence indicates that there are individual differences in host response upon inulin treatment due to the differences in host microbial composition before dietary intervention. Probably it is because of the multiple relationships among bacterial species (e.g., competition and mutualism), which play key roles in the degradation of inulin and the regulation of microbial structure. Thereby, analyzing the composition and function of initial gut microbiota is essential for improving the efficacy of prebiotics supplementation. Furthermore, considering that different structures of polysaccharides can be used by different microorganisms, the chemical structure of processed inulin should be tested before using prebiotic inulin to treat obesity related nonalcoholic fatty liver disease.

Keywords: Hepatic fat content; Individual differences; lipid metabolic disorders; physicochemical characterization; precision prebiotic.

Publication types

  • Review

MeSH terms

  • Gastrointestinal Microbiome*
  • Humans
  • Inulin / metabolism
  • Inulin / pharmacology
  • Inulin / therapeutic use
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Obesity / complications
  • Obesity / drug therapy
  • Prebiotics

Substances

  • Prebiotics
  • Inulin